<DOC>
	<DOCNO>NCT00412737</DOCNO>
	<brief_summary>This 2 arm study evaluate efficacy safety oseltamivir seasonal prophylaxis influenza immunocompromised participant ( represent transplant recipient ) . Transplant recipient enrol influenza circulate community randomize receive oseltamivir syrup capsule 30 milligram ( mg ) 75 mg daily ( depend body weight ) placebo 12 week . Influenza symptoms safety data record throughout study .</brief_summary>
	<brief_title>A Study Oseltamivir ( Tamiflu ) Seasonal Prophylaxis Influenza Immunocompromised Participants</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Oseltamivir</mesh_term>
	<criteria>Negative rapid diagnostic test influenza baseline ; Immunocompromised participant ( liver and/or kidney recipient allogenic hematopoietic stem cell transplant ) . Symptoms suggestive influenzalike illness ; limit fever , cough , nasal congestion ; Influenza vaccination 6 week prior randomization ; Positive rapid diagnostic test influenza ; Solid organ transplant within 6 month randomization ; Antiviral treatment influenza 2 week prior randomization .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>